Mesa Labs SVP sells shares after RSU exercises

Mesa Laboratories senior vice president of operations Brian David Archbold reported a mix of stock compensation activity and a modest sale of common shares.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Mesa Laboratories senior vice president of operations Brian David Archbold reported a mix of stock compensation activity and a modest sale of common shares. On June 18, 2026, he received a grant or award of 1,859 shares of common stock and exercised restricted stock units (RSUs) covering a total of 3,324 shares, converting them into common stock at a stated price of $95.10 per share for reporting purposes. Related RSU entries show derivative positions being fully converted into common stock.

On June 22, 2026, Archbold executed an open-market sale of 2,516 shares of Mesa Laboratories common stock at an average price of about $89.50 per share. After these transactions, he directly holds 6,377 common shares, indicating that a portion of the newly acquired stock was retained while some was sold for liquidity.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Archbold Brian David

Role SVP Operations

Sold 2,516 shs ($225K)

Approx. gross sale proceeds $225K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	2,516	$89.502	$225K
Exercise	Restricted Stock Units - 7	844	$0.00	$0.00
Exercise	Restricted Stock Units - 8	2,480	$0.00	$0.00
Exercise	Common Stock	844	$95.10	$80K
Exercise	Common Stock	2,480	$95.10	$236K
Grant/Award	Common Stock	1,859	$95.10	$177K

Holdings After Transaction: Restricted Stock Units - 7 — 0 contracts (Direct); Restricted Stock Units - 8 — 2,480 contracts (Direct); Common Stock — 6,377 shares (Direct)

Footnotes (5)

F1. Each RSU represents a contingent right to receive one share of the Issuer's common stock
F2. RSUs that vested June 21, 2024 and each of the next two anniversary dates
F3. Not Applicable
F4. RSUs that vest 1/3 on June 15, 2026 and each of the next 2 anniversary dates
F5. Shares represent common stock of Mesa Labs issued upon release of performance share units issued under the FY24-FY26 performance share unit program

Key Figures

Open-market sale: 2,516 shares at $89.5020 Post-sale holdings: 6,377 shares Stock grant: 1,859 shares at $95.10 +3 more

6 metrics

Open-market sale 2,516 shares at $89.5020 Common Stock sale on June 22, 2026

Post-sale holdings 6,377 shares Direct common stock held after June 22, 2026 sale

Stock grant 1,859 shares at $95.10 Grant/award acquisition on June 18, 2026

RSU exercises 3,324 shares at $95.10 Two derivative exercises into common stock on June 18, 2026

RSU series 8 exercised 2,480 RSUs Converted into common stock; each RSU equals one share

RSU series 7 exercised 844 RSUs Converted into common stock; remaining RSUs in this series now zero

Key Terms

Restricted Stock Units, performance share units, grant, award, or other acquisition, Exercise or conversion of derivative security, +1 more

5 terms

Restricted Stock Units financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant, award, or other acquisition financial

"Grant, award, or other acquisition"

Exercise or conversion of derivative security financial

"Exercise or conversion of derivative security"

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mesa Laboratories (MLAB) report for Brian David Archbold?

Mesa Laboratories reported that SVP Operations Brian David Archbold received a stock grant, exercised restricted stock units into common shares, and sold 2,516 common shares in an open-market transaction, leaving him with 6,377 common shares held directly.

How many Mesa Laboratories (MLAB) shares did Brian David Archbold sell and at what price?

Brian David Archbold sold 2,516 shares of Mesa Laboratories common stock at an average price of approximately $89.50 per share, according to the Form 4. This was an open-market sale classified under transaction code S.

What stock awards did Brian David Archbold receive from Mesa Laboratories (MLAB)?

Brian David Archbold received an award of 1,859 shares of Mesa Laboratories common stock on June 18, 2026. The filing classifies this as a grant or award acquisition under transaction code A, increasing his direct holdings before subsequent transactions.

Did Brian David Archbold exercise restricted stock units in Mesa Laboratories (MLAB)?

Yes. The Form 4 shows he exercised RSU-derived positions labeled as Restricted Stock Units – 7 and – 8 into a total of 3,324 common shares. Each RSU represents a contingent right to receive one share of Mesa Laboratories common stock.

How many Mesa Laboratories (MLAB) shares does Brian David Archbold hold after the reported transactions?

After the reported grant, RSU exercises, and subsequent sale, Brian David Archbold directly holds 6,377 shares of Mesa Laboratories common stock. This post-transaction balance is explicitly listed in the Form 4 for the June 22, 2026 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 01:02 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Archbold Brian David

(Last)

(First)

(Middle)

12100 W. 6TH AVENUE

(Street)

LAKEWOOD

COLORADO

80228

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		M		844	A	$95.1	4,554	D
Common Stock	06/18/2026		M		2,480	A	$95.1	7,034	D
Common Stock	06/18/2026		A		1,859⁽⁵⁾	A	$95.1	8,893	D
Common Stock	06/22/2026		S		2,516	D	$89.502	6,377	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units - 7	⁽¹⁾	06/18/2026		M			844	06/21/2024⁽²⁾	⁽³⁾	Common Stock	844	$0	0	D
Restricted Stock Units - 8	⁽¹⁾	06/18/2026		M			2,480	⁽³⁾	06/18/2025⁽⁴⁾	Common Stock	2,480	$0	2,480	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of the Issuer's common stock

2. RSUs that vested June 21, 2024 and each of the next two anniversary dates

3. Not Applicable

4. RSUs that vest 1/3 on June 15, 2026 and each of the next 2 anniversary dates

5. Shares represent common stock of Mesa Labs issued upon release of performance share units issued under the FY24-FY26 performance share unit program

	John Sakys under Power of Attorney by Brian Archbold	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR